Valuation: Amicus Therapeutics, Inc.

Market Cap 4.55B 3.98B 3.68B 3.43B 6.47B 430B 6.61B 44.26B 17.09B 212B 17.09B 16.71B 737B P/E 2024
-51.1x
P/E 2025 -162x
Enterprise Value 4.7B 4.11B 3.8B 3.55B 6.68B 444B 6.83B 45.71B 17.64B 219B 17.65B 17.26B 761B EV / Sales 2024
5.69x
EV / Sales 2025 7.18x
Free-Float
99.31%
Yield 2024 *
-
Yield 2025 -
1 day+0.21%
3 months+0.56%
6 months+1.68%
Current year+1.76%
Current year 14.2
Extreme 14.205
14.5
1 year 5.66
Extreme 5.66
14.5
3 years 5.51
Extreme 5.51
14.57
5 years 5.51
Extreme 5.51
14.57
10 years 4.41
Extreme 4.41
25.39
Date Insider Type Main position Quantity % Market Cap.
04-27Issuer sale

Director

446,194 0.1421%
04-27Issuer sale

Controller/Auditor

330,973 0.1054%
04-27Issuer sale

Director

310,136 0.0988%
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%-.--%+144.35%+15.27% 4.55B
+1.19%+5.78%-3.54%+2.17% 46.62B
+5.79%+16.17%+421.86%+634.63% 40.95B
+1.12%+15.18%+22.74%-12.71% 32.26B
+3.61%+6.69%+20.23%+62.38% 32.24B
+8.02%+6.35%+17.67%+34.73% 25.53B
+1.13%+15.66% - - 16.38B
+1.45%+17.35%+72.11%+127.60% 15.27B
+0.26%+4.78%+13.10%+17.54% 13.61B
-0.60%+6.32%+102.74%+96.28% 13.34B
Average +1.50%+10.45%+90.14%+108.66% 24.07B
Weighted average by Cap. +1.64%+11.37%+99.19%+143.15%

Financials

2024 2025
Net sales 528M 463M 427M 399M 751M 49.95B 768M 5.14B 1.98B 24.64B 1.98B 1.94B 85.55B 634M 555M 513M 479M 901M 59.96B 922M 6.17B 2.38B 29.58B 2.38B 2.33B 103B
Net income -56.11M -49.13M -45.35M -42.35M -79.72M -5.3B -81.54M -546M -211M -2.62B -211M -206M -9.09B -27.11M -23.74M -21.91M -20.46M -38.52M -2.56B -39.4M -264M -102M -1.26B -102M -99.58M -4.39B
Net Debt 194M 170M 157M 146M 275M 18.31B 282M 1.88B 727M 9.03B 727M 711M 31.37B 149M 130M 120M 112M 211M 14.07B 216M 1.45B 559M 6.94B 559M 547M 24.1B
Logo Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Employees
511
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. FOLD Stock